Dyne Therapeutics, Inc. (DYN)
| Market Cap | 894.57M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 51.21M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 14 |
| Last Price | $17.47 |
| Previous Close | $16.98 |
| Change ($) | 0.49 |
| Change (%) | 2.89% |
| Day's Open | 17.25 |
| Day's Range | 17.03 - 17.91 |
| Day's Volume | 143,767 |
| 52-Week Range | 13.50 - 32.31 |
Dyne Therapeutics Inc (NASDAQ: DYN) has announced new preclinical data from its myotonic dystrophy type 1 (DM1) program, including results demonstrating sustained knockdown of toxic human nuclear DMPK R...
- Robust Reduction in DMPK RNA in Multiple Muscles at Four Weeks in Novel In Vivo Model Developed by Dyne; Additional In Vitro Data Support Advancement of Lead DM1 Candidate -
- On Track to Submit INDs for DM1, DMD and FSHD Programs Between the Fourth Quarter of 2021 and the Fourth Quarter of 2022 -
Company to host webcast including leading DM1 expert, Dr. Charles Thornton, following presentations on May 14, 2021 Company to host webcast including leading DM1 expert, Dr. Charles Thornton, following ...
- Preclinical Data Further Validate FORCE™ Platform; Driving Toward IND Submissions for DM1, DMD and FSHD Programs Between Q4'21 and Q4'22 -
Seasoned Clinical Leader Brings Deep Experience in Drug Development, Including Approval of an Oligonucleotide Therapy in Neuromuscular Disease
Dr. Dugar Brings Over 20 Years of Experience in Medical Affairs, Clinical and Commercial Development, and Real-World Evidence, Including in Rare Muscle Disease
WALTHAM, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with ge...
- In Vivo Model Developed by Dyne Sets New Standard for Evaluating Pharmacodynamics in DM1 -
About DYN
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.
| Industry Pharmaceutical Preparation Manufacturing | IPO Date Sep 17, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol DYN |
Analyst Forecasts
According to 4 analysts, the average rating for DYN stock is "Buy." The 12-month stock price forecast is 38.75, which is an increase of 121.81% from the latest price.